SCHEMBL35805

SCHEMBL35805

CCCCCCCCCCCCOC=S.OC=S.OC=S

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 7/20 0.43
LPAR2 Q9HBW0 6/20 0.43
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
LPAR1 Q92633 3/20 0.40
THRB P10828 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.40
NAAA Q02083 1/20 0.39
CES2 O00748 1/20 0.38
GBA1 P04062 1/20 0.38
HCAR2 Q8TDS4 1/20 0.37
TSHR P16473 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35567 1.00 LPAR3 (0.43) LPAR3LPAR2CA12CA1CA2
SCHEMBL35365 1.00 LPAR3 (0.43) LPAR3LPAR2CA12CA1CA2
SCHEMBL35402 0.98 CA12 (0.41) LPAR3LPAR2CA12CA1CA2
SCHEMBL2067898 0.93 LPAR3 (0.43) LPAR3LPAR2CA12CA1CA2
SCHEMBL2068087 0.93
SCHEMBL2067511 0.93 LPAR3 (0.43) LPAR3LPAR2CA12CA1CA2
SCHEMBL14763440 0.93 LPAR3 (0.43) LPAR3LPAR2CA12CA1CA2
SCHEMBL5735068 0.93 LPAR3 (0.43) LPAR3LPAR2CA12CA1CA2
SCHEMBL35717 0.91 ALDH1A1 (0.41) LPAR3LPAR2CA12CA1CA2
SCHEMBL2068344 0.91

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243325-A1 PHOSPHORUS-31 MRI AGENTS UNIVERSITEIT TWENTE (NL) 2025-07-31 US disclosed
EP-4522679-A1 PHOSPHORUS-31 MRI AGENTS UNIVERSITEIT TWENTE (NL) 2025-03-19 EP disclosed
WO-2023217708-A1 PHOSPHORUS-31 MRI AGENTS UNIVERSITEIT TWENTE (NL) 2023-11-16 WO disclosed
US-10871595-B2 Polymers and nanogel materials and methods for making and using the same JOHNSON & JOHNSON VISION CARE, INC. (US) 2020-12-22 US disclosed
US-20200049858-A1 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE (US) 2020-02-13 US disclosed
US-10301465-B2 Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same JOHNSON & JOHNSON VISION CARE, INC. (US) 2019-05-28 US disclosed
US-20180341044-A1 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE (US) 2018-11-29 US disclosed
EP-3401342-A1 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME Johnson & Johnson Vision Care, Inc. (US) 2018-11-14 EP disclosed
EP-2566911-B1 NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND USES OF THE SAME JOHNSON & JOHNSON VISION CARE (US) 2018-10-24 EP disclosed
US-10073192-B2 Polymers and nanogel materials and methods for making and using the same JOHNSON & JOHNSON VISION CARE, INC. (US) 2018-09-11 US disclosed
US-20170051145-A1 NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE (US) 2017-02-23 US disclosed
US-9522980-B2 Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same JOHNSON & JOHNSON VISION CARE, INC. (US) 2016-12-20 US disclosed
EP-2855547-A2 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME Johnson & Johnson Vision Care Inc. (US) 2015-04-08 EP disclosed
EP-2855544-A2 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME Johnson & Johnson Vision Care Inc. (US) 2015-04-08 EP disclosed
WO-2013176886-A2 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE, INC. (US) 2013-11-28 WO disclosed
WO-2013177523-A2 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE, INC. (US) 2013-11-28 WO disclosed
US-20130317131-A1 POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE, INC. (US) 2013-11-28 US disclosed
EP-2566911-A1 NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND USES OF THE SAME Johnson & Johnson Vision Care, Inc. (US) 2013-03-13 EP disclosed
WO-2011140318-A1 NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND USES OF THE SAME JOHNSON & JOHNSON VISION CARE, INC. (US) 2011-11-10 WO disclosed
US-20110275734-A1 NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND METHODS FOR MAKING AND USING THE SAME JOHNSON & JOHNSON VISION CARE, INC. 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243325-A1 PHOSPHORUS-31 MRI AGENTS PHOSPHO1, PLCB3, INPP5B LPAR3 319/4885LPAR2 631/4885CA12 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.